DINTZIS ET AL. -- 09/757,774 Client/Matter: 041828-0276361

IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-43. (Cancelled).

- 44. (Previously presented) A method of making a non-immunogenic construct comprising at least two copies of an epitope of a T-dependent antigen bound to a pharmaceutically acceptable non-immunogenic carrier, which copies bind to a B cell membrane immunoglobulin receptor specific for the epitope but fail to form an immunon, comprising
- (a) providing a non-immunogenic soluble carrier that has been subjected to a preparative sizing technique to remove substantially most high molecular weight soluble carrier molecules, wherein the carrier is not poly (D-Glu/D-Lys), and an epitope molecule of a T-dependent antigen;
- (b) coupling two or more of the epitope molecules to the non-immunogenic soluble carrier that has been subjected to the preparative sizing technique of step (a) to yield a conjugate preparation; and
- (c) subjecting the conjugate preparation to size fractionation to yield a non-immunogenic epitope coupled construct,

thereby yielding a non-immunogenic construct which is free of high molecular weight immunostimulatory molecules.

- 45. (Previously presented) The method of claim 44, wherein the epitope comprises a peptide epitope.
- 46. (Previously presented) The method of claim 44, wherein the epitope comprises a carbohydrate epitope.
- 47. (Previously presented) The method of claim 44, wherein the epitope comprises a nucleic acid.
- 48. (Previously presented) The method of claim 47, wherein the nucleic acid comprises a phosphorothioate nucleic acid.

DINTZIS ET AL. -- 09/757,774 Client/Matter: 041828-0276361

- 49. (Previously presented) The method of claim 44, wherein the epitope comprises a glycolipid epitope.
- 50. (Previously presented) The method of claim 44, wherein the epitope is derived from an allergen.
- 51. (Previously presented) The method of claim 44, wherein the epitope is derived from an autoimmune antigen.
- 52. (Previously presented) The method of claim 44, wherein the non-immunogenic carrier comprises a dextran, a Ficoll, a carboxymethylcellulose, a polyvinyl alcohol, a synthetic polymer of D amino acids or a polyacrylamide.
 - 53. (Cancelled).
- 54. (Previously presented) The method of claim 44, wherein the non-immunogenic carrier comprises a protein oligomer.
- 55. (Previously presented) The method of claim 54, wherein the protein oligomer comprises an immunoglobulin or albumin.
- 56. (Previously presented) The method of claim 44, wherein after the preparative sizing technique the non-immunogenic carrier has a molecular weight of less than about 100,000 daltons.
- 57. (Previously presented) The method of claim 56, wherein after the preparative sizing technique the non-immunogenic carrier has a molecular weight of less than about 40,000 daltons.
 - 58. (Cancelled).
- 59. (Previously presented) The method of claim 44, wherein the preparative sizing technique comprises size exclusion gel chromatography.
- 60. (Previously presented) The method of claim 44, wherein the preparative sizing technique comprises ultrafiltration.
- 61. (Previously presented) The method of claim 44, wherein the copies of the epitope are bound to the non-immunogenic carrier by a spacer molecule.
- 62. (Previously presented) The method of claim 61, wherein the spacer molecule comprises an epsilon amino caproic acid or a delta amino valeric acid.

DINTZIS ET AL. -- 09/757,774 Client/Matter: 041828-0276361

- 63. (Cancelled).
- 64. (Cancelled).
- 65. (Previously presented) The method of claim 44, wherein the non-immunogenic construct comprises less than 20 copies of the epitope.
- 66. (Previously presented) The method of claim 44, wherein the non-immunogenic construct is immunosuppressive when administered in pharmacologically effective amounts.
- 67. (Previously presented) The method of claim 66, wherein the non-immunogenic construct suppresses T-cell dependent antibody production.
- 68. (Previously presented) The method of claim 44, wherein the non-immunogenic construct is tolerogenic when administered in pharmacologically effective amounts.
 - 69-87. (Cancelled).